TXG:NASDAQ10x Genomics, Inc. Analysis
Data as of 2026-09-15 - not real-time
$70.11
Latest Price
9/10Risk
Risk Level: High
Executive Summary
10x Genomics, Inc. is priced at $70.11 and its moving averages line up in bullish order, the shorter sitting above the longer. It has gained 48.3% over the past 30 days. RSI sits at 70.4, which reads as overbought, and MACD momentum is bullish. Price has been bracketed by support at $55.25 and resistance at $70.46.
The shares look overvalued, trading on 344.8 times earnings above a sector average of 30.0. Analyst price targets sit 25.6% below the current price. Revenue is contracting at 12.7% on a -12.2% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 70.6%, a beta of 2.23 and a maximum drawdown of 28.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against sell longer out, with 4/10 conviction on the long call.
The shares look overvalued, trading on 344.8 times earnings above a sector average of 30.0. Analyst price targets sit 25.6% below the current price. Revenue is contracting at 12.7% on a -12.2% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 70.6%, a beta of 2.23 and a maximum drawdown of 28.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against sell longer out, with 4/10 conviction on the long call.
Top Market Events
Biotech company 10x Genomics NASDAQ:TXG reported Q2 CY2026 results , but sales fell by 12.10x Genomics TXG has been upgraded to a Zacks Rank 2 Buy , reflecting growing optimism about the company's earnings...PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. Nasdaq: TXG , the life science technology leader...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- RSI at 70.4 signals overbought conditions
- Trading above the 200-day average of 30.20
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- RSI at 70.4 signals overbought conditions
- P/E of 344.8 versus sector average of 30.0
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- P/E of 344.8 versus sector average of 30.0
- Negative profit margin of -12.2%
- Analyst targets imply -25.6% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth-12.70%
Profit Margin-12.18%
P/E Ratio344.8
ROE-9.40%
ROA-5.05%
Debt/Equity9.54
P/B Ratio11.1
Op. Cash Flow$127.1M
Free Cash Flow$179.7M
Industry P/E30.0
Technical Analysis
TrendBullish
RSI70.4
Support$55.25
Resistance$70.46
MA 20$63.59
MA 50$53.83
MA 200$30.20
MACDBullish
VolumeDecreasing
Fear & Greed Index90.89
Valuation
Fair Value$20.65
Target Price$52.13
Upside/Downside-25.64%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.23
Volatility70.65%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.